

1 **Title**

2

3

4 **Long title**

5 Minimal transmission in an influenza A (H3N2) human challenge-

6 transmission model within a controlled exposure environment

7

8

9 **Short title**

10 Human influenza A transmission model in a controlled environment

11

12 **Authors**

13 Jonathan S. Nguyen-Van-Tam<sup>1</sup>, Ben Killingley<sup>1\*</sup>, Joanne Enstone<sup>1</sup>, Michael Hewitt<sup>1</sup>,

14 Jovan Pantelic<sup>2,#a</sup>, Michael L. Grantham<sup>2,#b</sup>, P. Jacob Bueno de Mesquita<sup>2</sup>, Robert

15 Lambkin-Williams<sup>3</sup>, Anthony Gilbert<sup>3</sup>, Alexander Mann<sup>3</sup>, John Forni<sup>3,#c</sup>, Catherine J.

16 Noakes<sup>4</sup>, Min Z. Levine<sup>5</sup>, LaShondra Berman<sup>5</sup>, Stephen Lindstrom<sup>5</sup>, Simon

17 Cauchemez<sup>6,#d</sup>, Werner Bischoff<sup>7</sup>, Raymond Tellier<sup>8</sup>, and Donald K. Milton<sup>2</sup>, for the

18 EMIT Consortium<sup>^</sup>.

19

20

21 **Affiliations**

22

23 <sup>1</sup> Health Protection and Influenza Research Group, Division of Epidemiology and  
24 Public Health, University of Nottingham School of Medicine, Nottingham, UK

25

1

26 <sup>2</sup> University of Maryland School of Public Health, Maryland Institute for Applied  
27 Environmental Health, College Park, MD, USA

28  
29 <sup>3</sup> hVIVO London, UK

30  
31 <sup>4</sup> University of Leeds School of Civil Engineering, Leeds, UK

32  
33 <sup>5</sup> Centers for Disease Control and Prevention, Influenza Division, Atlanta, GA, USA

34  
35 <sup>6</sup> Imperial College London, MRC Centre for Outbreak Analysis and Modelling,  
36 Department of Infectious Disease Epidemiology, London, UK

37  
38 <sup>7</sup> Wake Forest School of Medicine, Winston-Salem, NC, USA

39  
40 <sup>8</sup> University of Calgary, Cumming School of Medicine, Department of Pathology and  
41 Laboratory Medicine, Calgary, Alberta, CA

42  
43 <sup>#a</sup> Current Address: University of California, Center for the Built Environment,  
44 Berkeley, CA, USA

45  
46 <sup>#b</sup> Current Address: Missouri Western State University, St. Joseph, MO, USA

47  
48 <sup>#c</sup> Current Address: Department of Acute and Specialty Care, MSD, London, UK

49  
50 <sup>#d</sup> Current Address: Mathematical Modelling of Infectious Diseases Unit, CNRS  
51 UMR2000: Génomique évolutive, modélisation et santé (GEMS), Center of  
52 Bioinformatics, Biostatistics and Integrative Biology, Institut Pasteur, Paris, FR

53

54

55 \* Corresponding author

56 E-mail: [ben.killingley@nhs.net](mailto:ben.killingley@nhs.net) (BK)

57

58

59 ^ A complete list of the EMIT Consortium can be found in the Supporting

60 Information.

61

62

63 **Author Contributions**

64

65 Conceptualization: JSN-V-T, BK, JE; Methodology: all authors; Investigation: all  
66 authors except RT (face shield tests: WB); Formal analysis: JSN-V-T, BK, JE, AM,  
67 DKM, MG, MH, PJB, CJN; Data curation: all authors; Original draft preparation:  
68 JSN-V-T, BK, JE, DKM, AM, RLW, PJB; Review, editing and approval: all authors.  
69

70 **Abstract**

71           Uncertainty about the importance of influenza transmission by airborne  
72 droplet nuclei generates controversy for infection control. Human challenge-  
73 transmission studies have been supported as the most promising approach to fill this  
74 knowledge gap. Healthy, seronegative volunteer ‘Donors’ (n=52) were randomly  
75 selected for intranasal challenge with influenza A/Wisconsin/67/2005 (H3N2).  
76 ‘Recipients’ randomized to Intervention (IR, n=40) or Control (CR, n=35) groups  
77 were exposed to Donors for four days. IRs wore face shields and hand sanitized  
78 frequently to limit large droplet and contact transmission. One transmitted infection  
79 was confirmed by serology in a CR, yielding a secondary attack rate of 2.9% among  
80 CR, 0% in IR (p=0.47 for group difference), and 1.3% overall, significantly less than  
81 16% (p<0.001) expected based on a proof-of-concept study secondary attack rate and  
82 considering that there were twice as many Donors and days of exposure. The main  
83 difference between these studies was mechanical building ventilation in the follow-on  
84 study, suggesting a possible role for aerosols.

85

86

87

## 88 **Author summary**

89           Understanding the relative importance of influenza modes of transmission  
90 informs strategic use of preventive measures to reduce influenza risk in high-risk  
91 settings such as hospitals and is important for pandemic preparedness. Given the  
92 increasing evidence from epidemiological modelling, exhaled viral aerosol, and  
93 aerobiological survival studies supporting a role for airborne transmission and the  
94 potential benefit of respirators (and other precautions designed to prevent inhalation  
95 of aerosols) versus surgical masks (mainly effective for reducing exposure to large  
96 droplets) to protect healthcare workers, more studies are needed to evaluate the extent  
97 of risk posed airborne versus contact and large droplet spray transmission modes.  
98 New human challenge-transmission studies should be carefully designed to overcome  
99 limitations encountered in the current study. The low secondary attack rate reported  
100 herein also suggests that the current challenge-transmission model may no longer be a  
101 more promising approach to resolving questions about transmission modes than  
102 community-based studies employing environmental monitoring and newer, state-of-  
103 the-art deep sequencing-based molecular epidemiological methods.  
104  
105

## 106 **Introduction**

107           Influenza virus is a pathogen of global health significance, but human-to-  
108 human transmission remains poorly understood. In particular, the relative importance  
109 of the different modes of transmission (direct and indirect contact, large droplet, and  
110 aerosols (airborne droplet nuclei)) remains uncertain during symptomatic and  
111 asymptomatic infection (1–4).

112           The evidence base for influenza transmission is derived from studies that have  
113 assessed: virus deposition and survival in the environment; the epidemiology of  
114 disease; pharmaceutical and non-pharmaceutical interventions; animal models; and  
115 mathematical models of transmission. Those approaches have yet to produce  
116 conclusive data quantifying the relative importance of human-human transmission  
117 modes (1,2).

118           Infection control guidance for pandemic and seasonal influenza assumes that  
119 most transmission occurs during symptomatic infection, predominantly via large  
120 droplet spread at short range (1-2m) (1). Thus, social distancing measures are often  
121 proposed to mitigate the spread and impact of a pandemic; and hand washing and  
122 respiratory etiquette are promoted to reduce transmission. Evidence to support the  
123 possibility of aerosol transmission has grown over recent years (5–7). and leads to  
124 controversies about when and if filtering facepiece respirators (and other precautions  
125 designed to prevent inhalation of aerosols) versus surgical masks (mainly capable of  
126 reducing large droplets and some fine particles) should be used to protect healthcare  
127 workers, particularly during a severe pandemic (1,3,4,8–10).

128           An expert panel, after in-depth review of the challenges facing community-  
129 and workplace-based intervention studies and their failure thus far to provide  
130 definitive evidence regarding the relative contribution of the various modes,

131 concluded that a human challenge-transmission study would be a more promising  
132 direction for future research (11). Influenza challenge studies in humans have been  
133 conducted to investigate disease pathogenesis and the efficacy of antivirals and  
134 vaccines. Challenge studies assessing human-to-human transmission had not been  
135 performed (11). In 2009, we demonstrated proof-of-concept that healthy seronegative  
136 volunteers inoculated intranasally with influenza A/Wisconsin/67/2005 (A/WI), an  
137 H3N2 virus, would develop symptoms of influenza-like illness (ILI) and, under two  
138 days of household-like conditions without environmental controls, transmit infection  
139 to other seronegative volunteers. This suggested that larger scale human challenge-  
140 transmission models might be useful to evaluate transmission modes. A subsequent  
141 international workshop discussed the potential that human challenge-transmission  
142 studies, with appropriate interventions, monitoring of aerosol shedding, and  
143 environmental controls, could provide definitive results (12). Here, we report a large  
144 follow-on study, including design factors (Fig 1) aimed at assessing the importance of  
145 aerosol transmission in human-to-human transmission of influenza virus. Although  
146 the study did not achieve the intended level of transmission required for a more  
147 conclusive interpretation, it has revealed important lessons about potential airborne  
148 transmission and study design that represent critical knowledge to support effective  
149 large-scale, costly studies in this area.

150

151

## 152 **Results**

### 153 **Participation and safety**

154           Between January and June 2013, 496 seronegative (HAI $\leq$ 10 to the challenge  
155 virus antigen) volunteers underwent study-specific screening and 166 entered the  
156 quarantine unit, of whom 127 proved suitable for final study entry (Fig 2 – trial  
157 profile; S5 Appendix – volunteer baseline characteristics). Thirty-nine subjects were  
158 discharged before inoculation or exposure per protocol as described in Methods.  
159 Three separate quarantine EEs (exposure events) took place in March, April, and June  
160 2013 involving Q1: 41 (20 Donors; 11 CR; 10 IR), Q2: 31 (12 Donors; 9 CR; 10 IR)  
161 and Q3: 55 (20 Donors; 15 CR; 20 IR) subjects respectively, with 4 Donors and 4 to 7  
162 Recipients per exposure group. No serious adverse events were recorded in volunteers  
163 who commenced the study.

### 164 **Environmental control**

165           In Q1 relative humidity averaged 40% (Standard Deviation 9%), room  
166 temperature averaged 20.2 °C (0.4 °C) and CO<sub>2</sub> concentration averaged 1430ppm  
167 (110ppm). For Q2 and Q3, respectively, the corresponding values were 44% (4%),  
168 21.4°C (0.3 °C), 1810ppm (160ppm), and 57% (4%), 21.4°C (0.3 °C), 1810ppm  
169 (160ppm). Outdoor CO<sub>2</sub> concentration proxies, taken from the average of CO<sub>2</sub>  
170 measurements during 2:00am-3:00am were 418, 435, and 422 ppm, for Q1, Q2, and  
171 Q3, respectively.

### 172 **Donor status**

173           Donor status is summarised by quarantine study in Table 1. Over all  
174 quarantines combined, intranasal inoculation produced an infection rate of 81%  
175 (42/52) among inoculated volunteers. Of the 42 lab-confirmed infected Donors 25



176 (60%) had ILI and 10 (24%) were classified as asymptomatic (4 in Q1, 4 in Q2, and 2  
177 in Q3).

178

179 **Table 1. Infected Donor Status**

Q*	Infected/Inoculated n/n (%)	Clinical Illness n (% of Infected)			Laboratory-confirmed Infection n (% of Infected)		
		Symptomatic	Febrile	ILI	PCR-confirmed	PCR-confirmed & Seroconversion	Seroconversion by HAI : MN : Either
1	15/20 (75)	11 (73)	4 (27)	8 (53)	12 (80)	11 (73)	12 : 14 : 14
2	11/12 (92)	7 (64)	0 (0)	5 (45)	10 (91)	8 (73)	9 : 7 : 9
3	16/20 (80)	14 (88)	2 (13)	12 (75)	14 (88)	12 (75)	14 : 11 : 14
All	42/52 (81)	32 (76)	6 (14)	25 (60)	36 (86)	31 (74)	35 : 32 : 37

180 \*Quarantine number; Ten Donors had greater than anticipated pre-challenge immunity: 4 in Q1, 2 in Q2, 4 in Q3.

181

182 Ten Donors had greater immunity on admission, as identified by samples  
183 collected on day -2 (HAI>10 or MN≥80), than at their earlier screening. Four of the  
184 10 seroconverted (i.e. had a 4-fold rise in HAI or MN titres) between admission to  
185 quarantine and follow-up. Five of the 10 met laboratory case definition by qRT-PCR  
186 including all four who seroconverted. The one additional qRT-PCR positive Donor  
187 had positive swabs on study days 2 and 3 in Q2.

### 188 **Virus shedding by donors**

189 Overall, 36 Donors had nasopharyngeal swab (NPS) that tested positive by  
190 PCR for A/WI. Of these 36: 53% (n=19) were positive on day 1 post-challenge; 94%  
191 (34) on day 2; 97% (35) on day 3; 86% (31) on day 4; 92% (33) on day 5; and 67%  
192 (24) on day 6 (Fig 3).

193 Aerosol shedding was determined for 25 Donors on day 1, 31 on day 2, 30 on  
194 day 3, and 24 on day 4, and for a total of 36 person-days in Q1, 34 person-days in Q2,  
195 and 40 person-days in Q3. Aerosol shedding from infected Donors, detected in  
196 Gesundheit-II samples, is summarised in Table 2. Six (7%) of the coarse and 14

197 (16%) of the fine aerosol samples had detectable viral RNA. We observed aerosol  
 198 shedding from 11 (26%) of the 42 successfully infected Donors. The geometric mean  
 199 (GM) and geometric standard deviation (GSD) for coarse and fine aerosol viral RNA  
 200 copy numbers per 30-min sample were 3.1E+3 (3.3) and 5.3E+3 (4.6), respectively.  
 201 The maximum levels of shedding into coarse and fine aerosols were 2.79E+4 and  
 202 8.02E+4 RNA copies, respectively (Fig 3).

203

204 **Table 2. Exhaled Breath Viral RNA Detection and Copy Number Among**  
 205 **Infected Donors by Quarantine Event and Aerosol Fraction**

Q*			Coarse Aerosol (>5µm)			Fine Aerosol (≤5µm)		
	n Subjects	n Samples	Positive Subjects (%)	Positive Samples (%)	Positive Sample Mean <sup>†</sup>	Positive Subjects (%)	Positive Samples (%)	Positive Sample Mean <sup>†</sup>
1	15	27	1 (7)	1 (4)	2.79e+04	3 (20)	5 (19)	3.32e+04
2	11	30	3 (27)	3 (10)	2.16e+03	3 (27)	4 (13)	1.80e+04
3	16	32	2 (13)	2 (6)	1.73e+03	5 (31)	5 (16)	1.70e+03
All	42	89	6 (14)	6 (7)	6.31e+03	11 (26)	14 (16)	1.76e+04

206 \*Quarantine number;

207 <sup>†</sup>The arithmetic mean RNA copy number used positive samples only; The geometric means (GM) and geometric  
 208 standard deviations (GSD) over all positive samples were 3.14E+3 (3.33) and 5.31E+3 (4.59) for coarse and fine  
 209 aerosol samples, respectively.

210

## 211 Recipient status

212 Recipient status is shown in Table 3. There were similar rates of symptoms in  
 213 both IR and CR groups, although more in the CR group met the study definition of  
 214 ILI, the rates were not significantly different ( $p = 0.23$ ); no Recipient developed fever.  
 215 One infection was confirmed by serology (HAI increased from ≤10 to 40 and MN  
 216 increased from 10 to 320) in a CR subject who was symptomatic and whose  
 217 symptoms met the definition of ILI, but whose qRT-PCR evaluations were  
 218 persistently negative. Two other CR were transiently qRT-PCR positive but neither

219 met laboratory positivity criteria (Table S2). Both were asymptomatic and had no  
 220 change from baseline serology. Thus, there was only one, confirmed transmission  
 221 event. The CR and IR group SARs (2.9% and 0%) were not significantly different  
 222 (p=0.47).

223

224 **Table 3. Recipient Status**

Q*	Recipient <sup>†</sup>	Infected/Exposed n/n (%)	Clinical Illness n (% of Exposed)			Laboratory-confirmed Infection n (% of Exposed)		
			Symptomatic	Febrile	ILI	PCR-confirmed	PCR-confirmed & Seroconversion	Seroconversion by HAI : MN : Either
1	CR	0/11 (0)	4 (36)	0 (0)	3 (27)	0 (0)	0 (0)	0 : 0 : 0
	IR	0/10 (0)	2 (20)	0 (0)	1 (10)	0 (0)	0 (0)	0 : 0 : 0
2	CR	1/9 (11)	2 (22)	0 (0)	2 (22)	0 (0)	0 (0)	1 : 1 : 1
	IR	0/10 (0)	3 (30)	0 (0)	2 (20)	0 (0)	0 (0)	0 : 0 : 0
3	CR	0/15 (0)	6 (40)	0 (0)	4 (27)	0 (0)	0 (0)	0 : 0 : 0
	IR	0/20 (0)	6 (30)	0 (0)	2 (10)	0 (0)	0 (0)	0 : 0 : 0
All	CR	1/35 (3)	12 (34)	0 (0)	9 (26)	0 (0)	0 (0)	1 : 1 : 1
	IR	0/40 (0)	11 (28)	0 (0)	5 (13)	0 (0)	0 (0)	0 : 0 : 0

225 \*Quarantine number; Eleven recipients had greater than anticipated pre-challenge immunity: 3 CR and 3 IR for Q1;  
 226 no Q2 Recipients; 3 CR and 2 IR for Q3. None seroconverted.

227 <sup>†</sup>CR: Control Recipient; IR: Intervention Recipient.

228

229

230 To compare these results with the SAR from the proof-of-concept study, we  
 231 recomputed the latter results using the current, more stringent outcome criteria. The  
 232 adjusted proof-of-concept SAR was 8.3% giving an expected SAR of 16%. The  
 233 observed SAR for the current study was not significantly different than that of the  
 234 adjusted SAR from the proof-of-concept study, but was significantly lower than the  
 235 expected doubling of the SAR (1.3% overall, p<0.0001; and 2.9% for CR, p=0.035).  
 236 Comparisons of observed and expected SAR using the proof-of-concept study  
 237 outcome definitions were also statistically significant (p<0.0001, S6 Appendix).

238 **Data availability**

239           Data required for reproduction of analyses is available upon request. Scripts  
240 and other documentation to reproduce analyses are available at Digital Repositories at  
241 the University of Maryland (13) and  
242 [https://gitlab.com/jacobbueno/emit\\_quarantine\\_main](https://gitlab.com/jacobbueno/emit_quarantine_main).

243

244

## 245 **Discussion**

246           To our knowledge, this is the largest human influenza challenge-transmission  
247 study undertaken to date. We applied measures to control and standardise  
248 environmental conditions and ventilation rates within and between exposure events, to  
249 emulate as far as possible indoor winter conditions when respiratory virus spread is  
250 maximal. We particularly sought to maintain low humidity conditions which have  
251 been associated with enhanced transmission (14) and increased virus viability (15),  
252 together with a low ventilation rate to maximize recipient exposure to airborne virus.  
253 The near absence of transmission to control Recipients suggests contact and large  
254 droplet spray did not contribute substantially to transmission under the conditions  
255 used in these EEs. The significantly lower than expected SAR in this study compared  
256 with the proof-of-concept study, which had much lower ventilation rates, suggests  
257 aerosols as an important mode of influenza virus transmission in this model. The  
258 overall low SAR suggests that Donors in this model were minimally contagious and  
259 prevents definitive assessment of the modes of transmission.

260           Having reported an SAR of 25% (3/12) in our earlier proof-of-concept study,  
261 we expected to observe an SAR of >25%, having doubled both the duration of the  
262 exposure and the number of Donors in each quarantine (16). Indeed, the study was  
263 designed to examine an SAR of 40% in CR versus 20% in IR which would have  
264 required 125 Recipient volunteers; this was not met (n=75) and the study was  
265 underpowered.

266           However, the outcome criteria used in the proof-of-concept study, which  
267 included as positive a single NPS positive by qRT-PCR without seroconversion, were  
268 made more stringent in the present study by requiring two or more NPS positive by  
269 qRT-PCR in the absence of seroconversion (S6 Appendix). Applying the proof-of-

270 concept criteria to the current study gives an SAR of 4% (3/75) overall, while  
271 applying the stricter criteria used in this study to the proof-of-concept study gives an  
272 SAR of 8.3% (1/12) rather than 25%. Given the lower than planned enrolment and the  
273 stricter outcome criteria, this study was doubly underpowered.

274         These observations raise two questions: 1) Why were SARs, using stringent  
275 criteria, low in both studies and what are the implications for future human challenge-  
276 transmission studies? 2) Why was the SAR significantly lower in the present study  
277 compared with the expected doubling of the rate observed for the proof-of-concept?

278         The low SAR in these studies suggests that, unless a much greater SAR can be  
279 achieved, type II error associated with underpowering will be a major obstacle to  
280 successful use of human challenge-transmission studies. Potential areas to consider  
281 addressing in order to raise the SARs in future studies include the virus used, the route  
282 of inoculation, susceptibility of the human volunteers, the rate of viral shedding into  
283 NPS and aerosols, and reducing ventilation of exposure rooms.

284         In the proof-of-concept (2009) and follow-on (2013) studies we used a GMP  
285 A/WI challenge virus manufactured by Baxter BioScience (Vienna, Austria). Both  
286 studies produced similar clinical and serological infection rates (typically 60-70% and  
287 70-75%, respectively) after inoculation via nasal instillation, and similar spectrums of  
288 clinical illness severity in Donors. These rates were higher than reported by a previous  
289 study using lower doses of the same viral preparation (17) and consistent with rates  
290 reported in a review of 56 challenge studies (18). The illnesses we observed were  
291 similar to the range seen in healthy adults in the community, from asymptomatic to  
292 febrile symptomatic infection (19). Thus, skewed illness severity does not seem to  
293 explain the low SAR.

294           The virus preparation has been used in other human challenge studies with  
295 similar rates of infection via nasal instillation (20). Using deep sequencing, Sobel  
296 Leonard and colleagues showed that a sample of the Baxter stock “was at least  
297 partially adapted” to the egg and/or tissue environments in which it was produced  
298 (20). They also found that nasal instillation of the stock into human volunteers  
299 resulted in rapid purification selection, although a fixed variant in the HA gene  
300 remained. We have performed a BLAST search and identified the fixed variant  
301 (G70A/D8N) in deposited sequences of wild-type H3N2 viruses. This suggests that,  
302 on its own, the fixed HA variant is unlikely to have been a key alteration. These  
303 results suggest that it is unlikely that the virus stock was the primary cause of the low  
304 SARs. But, the impact of positive selection of the challenge virus for growth in the  
305 production environment, rather than for human transmissibility, remains a potential  
306 contributing factor to consider in choosing challenge viruses for future transmission  
307 studies.

308           The route of infection with influenza virus is known to matter in the setting of  
309 experimental infection, with aerosolized virus infectious at lower doses and more  
310 likely to result in ‘typical influenza-like disease’ (fever plus cough) than intranasal  
311 inoculation (21,22). This anisotropic property (23) of influenza virus is not unique  
312 among respiratory viruses; e.g. it is exploited by the live, unattenuated adenovirus  
313 vaccine (24). The implication for human challenge-transmission studies, however,  
314 may be that increased rates of lower respiratory tract infection via aerosol inoculation  
315 might be required to achieve sufficiently high rates of donors with fever, cough, and  
316 contagiousness to achieve a useful SAR.

317           In the current quarantine-based human challenge-transmission model,  
318 consistent with historical precedent, screening for susceptibility was undertaken

319 primarily by HAI antibody screening, although it is recognised that screening by MN  
320 titre or other assays (25,26) could be an alternative or adjunctive approach. The exact  
321 correlates of immunity and severity using novel immunological assays have not been  
322 validated and selecting subjects based on these assays would have added substantial  
323 complexity and costs. Six Donors and five Recipients in the present study were  
324 discovered, in retrospect, to have seroconverted during the 3 to 56-day interval prior  
325 to entering the quarantine facility, despite having as short a delay as possible between  
326 final screening for HAI and quarantine entry. However, the majority of Donors and  
327 Recipients were susceptible according to the results of microneutralization tests. Prior  
328 immunity, as measured by the HAI and MN assays, does not therefore, appear to have  
329 been a major limitation nor account for failure to transmit from readily infected  
330 Donors to identically screened Recipients. Regarding future studies, as novel immune  
331 correlates of influenza protection and severity become established, additional  
332 approaches beyond HAI and MN assays could be employed for volunteer selection.  
333 This might enable selection of those likely to become infected, febrile, and have  
334 greater symptomatology including more frequent and greater levels of cough and  
335 runny nose. Unfortunately, such screening might also dramatically reduce the yield of  
336 suitable volunteers and substantially increase overall study costs.

337         Results from serial nasopharyngeal swabs in Donors indicate that over 80%  
338 were positive by qRT-PCR testing on one or more post-challenge days. Viral load  
339 detected by swabs was substantial with qRT-PCR Ct values in the mid 20s on days  
340 two and three (Fig 3). Thus, failure to shed virus into nasal secretions cannot explain  
341 the low SARs. Minimal transmission despite days of prolonged exposure to Donors  
342 shedding virus into nasal secretions provides strong evidence that contact and large  
343 droplet transmission are not important in this model.



344           The results from breath sampling with the Gesundheit-II device indicate that  
345   26% (11/42) of infected Donors had virus detectable in exhaled air during the same  
346   period. By comparison, virus shedding into exhaled breath was detected in 84% (119  
347   of 142) of influenza cases selected on the basis of having fever or a positive rapid test  
348   and sampled on one to three days post onset of symptoms, mostly recruited from  
349   young adults on a college campus (7). When compared on a per-sample basis,  
350   infected Donors shed detectable virus less frequently than naturally infected college  
351   campus cases (7) in both coarse (7% and 40%, respectively) and fine aerosols (15%  
352   and 76%); all assays for both groups were performed in the same laboratory using the  
353   same methods. However, when the comparison was limited to positive aerosol  
354   samples from each study population, the average quantities of virus detected were  
355   similar (within 1 log), for the Donors as for the college community cases (GM coarse  
356    $3.1\text{E}+3$  and  $1.2\text{E}+4$ , GM fine  $5.3\text{E}+3$  and  $3.8\text{E}+4$ , respectively). The maximum  
357   exhaled breath viral aerosol from the 11 Donors was two to four logs lower than from  
358   the college campus cases selected for having fever or a high viral load in the NPS  
359   (maximum coarse  $2.8\text{E}+4$  and  $4.3\text{E}+8$ , and maximum fine  $8.0\text{E}+4$  and  $4.4\text{E}+7$ ,  
360   respectively) (7). While this difference may merely represent the low probability of  
361   sampling from the tail of a log-normal distribution with only 11, as compared with  
362   119 cases, it may be relevant to the low SAR in the challenge-transmission model if  
363   aerosols disseminated by more symptomatic individuals, such as the selected  
364   community cases, and rare supershedders account for most transmission. If aerosols  
365   are largely derived from the lower respiratory tract, as has been suggested by analysis  
366   of the college community cases, this would also suggest that future challenge-  
367   transmission studies should employ methods designed to increase the frequency of  
368   lower respiratory tract infection.

369           The proof-of-concept study was conducted in a hotel room with closed  
370 windows and thermal control provided only by a recirculating air conditioning unit.  
371 While the ventilation rate was not measured, it was likely to have been extremely low  
372 for the number of occupants, with only small, intermittent, bathroom extract and  
373 natural building infiltration providing fresh air. The ventilation rate of 4 l/s/person  
374 during the main study was low compared to 10 l/s/person recommended in UK design  
375 standards (27) but was likely substantially greater than in the proof-of-concept study.  
376 This would have produced significantly higher viral aerosol concentrations during the  
377 proof-of-concept EEs, assuming similar generation rates from Donors in both  
378 experiments. Given that the Donors in the two studies were similar in other respects,  
379 differences in shedding rates seem unlikely. Therefore, the difference in SAR between  
380 this study and the expected SAR based on design changes and prior results are  
381 possibly due to differing ventilation conditions. The implication for future challenge-  
382 transmission studies, given that the ventilation rate in the current study was as low as  
383 possible with a single pass ventilation system, is that recirculating air conditioning  
384 systems similar to that in the proof-of-concept study should be employed to limit  
385 dilution ventilation and maximize exposure to aerosols. This will be especially  
386 important if Donors in future studies continue to represent the lower end of the  
387 aerosol shedding spectrum seen in naturally infected cases.

388           Achieving temperature and humidity to simulate winter conditions was  
389 challenging, particularly in Q3, conducted in June 2013 when the average external  
390 conditions were 16°C and 64% relative humidity. It was necessary to strike a balance  
391 between volunteer comfort and conditions favourable to transmission, both of which  
392 were constrained by the capability of the mechanical systems in the building.  
393 However, the relative humidity in the current study overlapped with that during the

394 proof-of-concept study, which ranged between 38 and 53%, and thus, eliminated  
395 humidity as a potential explanation for the difference in transmission rates.

396         Despite this study not having produced the planned SAR, it yields important  
397 findings. First, although fewer viral challenged subjects had virus-laden aerosols than  
398 seen in people with natural infections presenting with influenza-like symptoms, those  
399 volunteers who did produce viral aerosols did so at a rate similar to the average  
400 symptomatic naturally infected case. Second, given that a subset of the infected  
401 volunteers had moderate viral aerosol shedding in this model, observation of  
402 transmission via aerosols in quarantine studies may be strongly dependent on the  
403 dilution ventilation rate. Third, low risk of transmission to Control Recipients  
404 suggests that contact and large droplet spray transmission were not important modes  
405 of transmission in this model. The overall low SAR compared to that observed in the  
406 proof-of-concept study suggests that, given the main difference between the studies  
407 was the indoor air ventilation rate, aerosol transmission may be an important mode of  
408 influenza virus transmission between adults. Finally, sensitivity of transmission to  
409 details of the Donors selected, environment, and activity during exposure events,  
410 suggest that if a successful transmission model can be developed, carefully designed  
411 studies may be useful for investigating specific, targeted intervention strategies for  
412 prevention of specific transmission modalities. However, sensitivity to experimental  
413 conditions also demonstrates that it will be challenging to generalize the results of the  
414 quarantine-based transmission model to broad conclusions about the relative  
415 importance of aerosol, droplet spray, and contact modes of transmission. These  
416 complexities of the challenge-transmission model suggest that community-based  
417 transmission studies employing deep-sequencing based molecular epidemiologic  
418 methods in natural experiments, e.g. comparing high and low ventilation dormitories

419 or barracks, may be more attractive alternatives than previously thought.

420 Unfortunately, although an important role for aerosols in transmission of influenza, at

421 least between adults, is hinted at when comparing the proof-of-concept and current

422 studies, this challenge model cannot provide a definitive answer to the importance of

423 this mode for influenza virus transmission between humans.

424

425

## 426 **Materials and methods**

### 427 **Ethics statement**

428           The randomized challenge-transmission trial took place from March to June  
429 2013 in a closed quarantine facility, with written informed consent from healthy  
430 volunteers in accordance with the principles of the Declaration of Helsinki, in  
431 compliance with UK regulatory and ethical (IRB) requirements (under auspices of the  
432 UK Health Research Authority (HRA) National Research Ethics Service (NRES)  
433 Committee London – City & East; reference number 12/LO/1277), and registered  
434 with ClinicalTrials.gov (number NCT01710111).

### 435 **Overview**

436           Volunteers, screened for serologic susceptibility, were randomly selected for  
437 intranasal challenge with A/WI (16) – becoming ‘Donors’. After allowing for a short  
438 incubation period, Donors were introduced to other sero-susceptible volunteers –  
439 ‘Recipients’ – under controlled household-like conditions for four days. Recipients  
440 were randomised as Intervention Recipients (IR) or Control Recipients (CR). IRs  
441 wore face shields evaluated to interrupt large droplet transmission but to be  
442 permissive to aerosols (S3 Appendix); in addition, IRs hand sanitised (using alcohol-  
443 based Deb® InstantFOAM, 72% ethyl alcohol) once every 15 minutes to minimise  
444 the possibility of contact transmission. IRs were only allowed to touch face via single-  
445 use wooden spatulas. Thus, IRs would be exposed to influenza only via aerosols. CRs  
446 did not wear face shields or use hand sanitiser and were allowed to touch face freely;  
447 therefore, CRs would have been exposed via all routes of transmission consistent with  
448 close proximity human-human contact. Fig 1 shows an overview of the study design.

### 449 **Influenza Virus**

450 Influenza A/WI manufactured and processed under current good  
451 manufacturing practices (cGMP) was obtained from Baxter BioScience, (Vienna,  
452 Austria). Stocks of this virus preparation have been sequenced and its evolution in the  
453 upper respiratory track of inoculated volunteers extensively analysed (20).

#### 454 **Screening**

455 Volunteers were screened from 3-56 days in advance of the experiment to  
456 determine humoral immunity to A/WI before undergoing further screening against  
457 inclusion and exclusion criteria (S4 Appendix). Volunteers needed to be healthy,  
458 between the ages of 18 and 45 years, not living with anyone deemed at high risk of  
459 influenza complications on discharge, and not to have had a seasonal influenza  
460 vaccine in the last 3 years. Blood samples from volunteers were collected  
461 immediately before quarantine entry for repeat serology, although results were not  
462 available until after the study. An initial screening haemagglutination inhibition assay  
463 (HAI) titre of  $\leq 10$  was considered evidence of susceptibility to infection.

#### 464 **Power calculation**

465 We calculated, based on the reported SAR of the proof-of-concept study (16)  
466 (S4 Appendix), that over a range of scenarios the statistical power of the whole study  
467 would be 63%-84%, typically 80% in the most realistic scenario, if a sample size of  
468 125 Recipients was achieved (70 IR, 55 CR). To increase the SAR from that observed  
469 in the proof-of-concept study, we opted to inoculate 4 (rather than 2) Donors per 5  
470 Recipients and to conduct exposure events on days 1-4 (rather than 2-3) post  
471 inoculation.

#### 472 **Pre-exposure**

473 Screened, eligible, volunteers entered a closed, quarantine unit on Day -2 and  
474 were randomised to Donor or Recipient (IR and CR) groups; thereafter Donors and

475 Recipients were segregated. Donors and Recipients were immediately screened for a  
476 panel of 7 imported ‘contaminant’ respiratory viruses (influenza A, B; adenovirus;  
477 respiratory syncytial virus; parainfluenza 1, 2, 3) by a direct fluorescence antibody  
478 assay (DFA) (LIGHT DIAGNOSTICS™ SimulFluor1 Respiratory Screen, Merck  
479 Millipore) and any with a positive test were immediately discharged. On day 0,  
480 Donors were inoculated intranasally, via pipette in a supine position, with 0.5ml per  
481 nostril of a suspension containing  $5.5 \log_{10}$ TCID<sub>50</sub>/ml of influenza A/WI (17,28).

## 482 **Exposure Events**

483         The study was conducted in three, separate, identically-designed quarantine  
484 events (Q1, Q2, and Q3). From Day 1 to Day 4 of each quarantine event, all  
485 volunteers took part in an Exposure Event (EE). Individual Donors and Recipients  
486 were each allocated to a single exposure room per day where they interacted at close  
487 distances for approximately 15 hours/day, for four consecutive days. In-room staff  
488 supervised activities such as playing board games, pool, and table football, and  
489 watching films, whilst ensuring that volunteers mixed freely, and that IRs complied  
490 with face shield use, hand sanitisation, and no-touch-face rules. Donor, IR and CR  
491 groups were moved into different corners of the rooms for meal breaks, and Donor  
492 and Recipient groups were housed separately at night, including further separation  
493 and withdrawal of any Recipients with symptoms to prevent any contamination of the  
494 results by Recipient-Recipient secondary transmission. Five exposure rooms were  
495 used ranging from 17-30m<sup>2</sup> floor area and 50-87m<sup>3</sup> volume. Four Donors were non-  
496 randomly allocated to each exposure group to ensure even distribution of subjects  
497 actively shedding virus. This was achieved by assessing symptom scores and the  
498 results of influenza rapid tests (Quidel Sofia®) performed on Days 1 and 2. From Day  
499 2 onwards, Donors remained in their allocated group and were not redistributed

500 further. Once assigned to an exposure group, Recipients remained in the same group  
501 until the end of the EE or until they developed ILI and were withdrawn to a separate  
502 isolation area. On each day of EE, each exposure group rotated to a different exposure  
503 room.

#### 504 **Environmental controls**

505 Each exposure room was assessed pre-quarantine by building and ventilation  
506 engineers and modified to achieve a ventilation rate of approximately  
507 4L/second/person (based on planned occupancy during EEs), temperature 18-22°C,  
508 and relative humidity 45-65%, to produce conditions favourable to influenza  
509 transmission (14), balanced against tolerability for occupants, and the capability of  
510 building systems to provide controlled environments comparable across all three  
511 quarantine studies. During each EE, rooms were monitored at 5-minute intervals for  
512 CO<sub>2</sub> concentration (as a proxy for ventilation rate), temperature and humidity;  
513 heating, cooling and humidity were remotely adjusted to maintain optimal conditions.

#### 514 **Clinical assessment**

515 All subjects underwent thrice daily monitoring of respiratory and systemic  
516 symptoms; each symptom was reported as grade 0 (not present) to 3 (severe). Paired  
517 venous blood specimens for serology were taken on Day -2 and Day 28. NPS were  
518 taken daily from all subjects. Respiratory specimens were analysed by quantitative  
519 reverse-transcriptase PCR (qRT-PCR) and serological specimens by HAI and  
520 microneutralisation (MN) assays. The qRT-PCR and HAI were performed in  
521 duplicate at the MRC University of Glasgow Centre for Virus Research (with Fast  
522 Track Diagnostics qRT-PCR kit) and the U.S. Centers for Disease Control and  
523 Prevention (CDC), Atlanta; MN assays were performed by CDC as described  
524 previously (29).



525 **Exhaled breath sampling**

526 Donors were assigned to provide exhaled breath samples on two, randomly  
527 selected days within the exposure event, collected using a Gesundheit-II cone  
528 collection apparatus allowing for fractionation of particle sizes into ‘fine’  $<5\mu\text{m}$  and  
529 ‘coarse’  $\geq 5\mu\text{m}$  aerosol samples (8,30). Each sample collection session lasted for 30  
530 minutes. Breath samples were concentrated, extracted, stored at  $-80^{\circ}\text{C}$ , and evaluated  
531 by qRT-PCR using protocols and materials specified by the CDC with RNA copy  
532 number estimated as previously described (7).

533 **Discharge**

534 After completion of the EE, Donors were discharged on active treatment with  
535 oseltamivir (75mg b.i.d. 5 days), whereas Recipients were observed for 7 days, then  
536 discharged with oseltamivir on day 8. All volunteers attended for 28-day ( $\pm 3$  days)  
537 post virus exposure outpatient follow-up and study dismissal.

538 **Outcome Definitions**

539 Respiratory symptoms were defined as self-reported grade  $\geq 1$  of runny nose,  
540 stuffy nose, sneeze, sore throat, cough, or shortness of breath ‘lasting  $\geq 24$  hours’ (S4  
541 Appendix). Fever was defined as temperature  $>37.9^{\circ}\text{C}$ . Symptomatic was defined as  
542 evidence of any respiratory symptom lasting  $\geq 24$  hours during study days 1-6.  
543 Influenza-like Illness (ILI) was defined as an illness  $>24$  hours duration with: either  
544 fever and at least one respiratory symptom; or two or more symptoms of grade  $\geq 1$ ,  
545 one of which must have been respiratory; eligible non-respiratory symptoms were  
546 headache, muscle/joint ache, and malaise; lasting  $\geq 24$  hours means report of a  
547 respiratory symptom during 3/3 observations within a single day, or at least once per  
548 day over two consecutive days. Laboratory confirmed infection was defined as: a 4-  
549 fold or greater rise in HAI or MN titres between Day -2 (baseline) and Day 28; or two

550 or more positive NPS test results by qRT-PCR. These differed from the proof-of-  
551 concept study, which used seroconversion or a single positive nasal wash (S6  
552 Appendix).

### 553 **Statistics**

554 Comparisons were made between groups using Fisher's exact tests for  
555 binomial proportions and between observed and expected outcomes using binomial  
556 tests. Tests were two-tailed. All data to reproduce analyses is available from the  
557 EMIT Consortium upon request.

558

559

560 **Acknowledgements**

561           The authors thank Blanca Beato Arribas and William Booth of BSRIA  
562 Limited, Chang Chen, Sheryl Ehrman, Neil Ferguson, Lisa Grohskopf, F. Liaini  
563 Gross, Andrew Hayward, Ashley Kang, Jacqueline Katz, John Oxford, Massimo  
564 Palmarini, Walt Adamson, Jennifer Wang, and the hVivo clinical team for their  
565 advice and contributions to the study. The authors are grateful to other Scientific  
566 Advisory Board members: Allan Bennett, Ben Cowling, and Arnold Monto.

567

568

## 569   **References**

- 570   1. Brankston G, Gitterman L, Hirji Z, Lemieux C, Gardam M. Transmission of influenza A in  
571       human beings. *Lancet Infect Dis*. 2007 Apr;7(4):257–65.
- 572   2. Killingley B, Nguyen-Van-Tam J. Routes of influenza transmission. *Influenza and Other*  
573       *Respiratory Viruses*. 2013 Sep;7:42–51.
- 574   3. Tellier R. Review of aerosol transmission of influenza A virus. *Emerging Infect Dis*. 2006  
575       Nov;12(11):1657–62.
- 576   4. Tellier R. Aerosol transmission of influenza A virus: a review of new studies. *J R Soc*  
577       *Interface*. 2009 Dec 6;6 Suppl 6:S783-790.
- 578   5. Cowling BJ, Ip DKM, Fang VJ, Suntarattiwong P, Olsen SJ, Levy J, et al. Aerosol  
579       transmission is an important mode of influenza A virus spread. *Nat Commun*.  
580       2013;4(1):1935.
- 581   6. Kormuth KA, Lin K, Prussin AJ, Vejerano EP, Tiwari AJ, Cox SS, et al. Influenza Virus  
582       Infectivity Is Retained in Aerosols and Droplets Independent of Relative Humidity. *J*  
583       *Infect Dis*. 2018 Jul 24;218(5):739–47.
- 584   7. Yan J, Grantham M, Pantelic J, Bueno de Mesquita PJ, Albert B, Liu F, et al. Infectious  
585       virus in exhaled breath of symptomatic seasonal influenza cases from a college  
586       community. *Proc Natl Acad Sci USA*. 2018 Jan 30;115(5):1081–6.
- 587   8. Milton DK, Fabian MP, Cowling BJ, Grantham ML, McDevitt JJ. Influenza Virus  
588       Aerosols in Human Exhaled Breath: Particle Size, Culturability, and Effect of Surgical  
589       Masks. Fouchier RAM, editor. *PLoS Pathogens*. 2013 Mar 7;9(3):e1003205.
- 590   9. Makison Booth C, Clayton M, Crook B, Gawn JM. Effectiveness of surgical masks against  
591       influenza bioaerosols. *Journal of Hospital Infection*. 2013 May 1;84(1):22–6.
- 592   10. Bischoff WE, Swett K, Leng I, Peters TR. Exposure to Influenza Virus Aerosols During  
593       Routine Patient Care. *J Infect Dis*. 2013 Apr 1;207(7):1037–46.
- 594   11. Killingley B, Enstone J, Booy R, Hayward A, Oxford J, Ferguson N, et al. Potential role  
595       of human challenge studies for investigation of influenza transmission. *Lancet Infect*  
596       *Dis*. 2011 Nov;11(11):879–86.
- 597   12. Snider D, Bridges C, Weissman D. Meeting summary of the workshop ‘Approaches to  
598       better understand human influenza transmission’.’ In Tom Harkin Global  
599       Communications Center, Centers for Disease Control and Prevention, Atlanta, Georgia:  
600       Centers for Disease Control and Prevention; 2010. Available from:  
601       [https://www.cdc.gov/influenzatransmissionworkshop2010/pdf/Influenza\\_Transmission\\_](https://www.cdc.gov/influenzatransmissionworkshop2010/pdf/Influenza_Transmission_Workshop_Summary_508.pdf)  
602       *Workshop\_Summary\_508.pdf*
- 603   13. Bueno de Mesquita PJ, Jacob P. Code to reproduce analysis of manuscript: Minimal  
604       transmission in an influenza A (H3N2) human challenge-transmission model with  
605       exposure events in a controlled environment. 2019 Dec 10 [cited 2019 Dec 10];  
606       Available from: <http://drum.lib.umd.edu/handle/1903/25315>
- 607   14. Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on  
608       relative humidity and temperature. *PLoS Pathog*. 2007 Oct 19;3(10):1470–6.

- 609 15. Yang W, Elankumaran S, Marr LC. Relationship between Humidity and Influenza A  
610 Viability in Droplets and Implications for Influenza's Seasonality. *PLOS ONE*. 2012  
611 Oct 3;7(10):e46789.
- 612 16. Killingley B, Enstone JE, Greatorex J, Gilbert AS, Lambkin-Williams R, Cauchemez S,  
613 et al. Use of a human influenza challenge model to assess person-to-person  
614 transmission: proof-of-concept study. *J Infect Dis*. 2012 Jan 1;205(1):35–43.
- 615 17. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, Lucas J, et al. Gene expression  
616 signatures diagnose influenza and other symptomatic respiratory viral infections in  
617 humans. *Cell Host Microbe*. 2009 Sep 17;6(3):207–17.
- 618 18. Carrat F, Vergu E, Ferguson NM, Lemaître M, Cauchemez S, Leach S, et al. Time lines  
619 of infection and disease in human influenza: a review of volunteer challenge studies.  
620 *Am J Epidemiol*. 2008 Apr 1;167(7):775–85.
- 621 19. Hayward AC, Fragaszy EB, Bermingham A, Wang L, Copas A, Edmunds WJ, et al.  
622 Comparative community burden and severity of seasonal and pandemic influenza:  
623 results of the Flu Watch cohort study. *Lancet Respir Med*. 2014 Jun;2(6):445–54.
- 624 20. Sobel Leonard A, McClain MT, Smith GJD, Wentworth DE, Halpin RA, Lin X, et al.  
625 Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a  
626 Selective Bottleneck and Only Limited Intra-host Genetic Diversification. *J Virol*. 2016  
627 Dec 15;90(24):11247–58.
- 628 21. Alford RH, Kasel JA, Gerone PJ, Knight V. Human influenza resulting from aerosol  
629 inhalation. *Proc Soc Exp Biol Med*. 1966 Jul;122(3):800–4.
- 630 22. Henle W, Henle G, Stokes J, Maris EP. Experimental Exposure of Human Subjects to  
631 Viruses of Influenza. *J Immunol*. 1946;52(2):145–65.
- 632 23. Milton DK. What was the primary mode of smallpox transmission? Implications for  
633 biodefense. *Front Cell Infect Microbiol*. 2012;2:150.
- 634 24. Couch RB, Chanock RM, Cate TR, Lang DJ, Knight V, Huebner RJ. Immunization with  
635 types 4 and 7 adenovirus by selective infection of the intestinal tract. *Am Rev Respir*  
636 *Dis*. 1963 Sep;88:SUPPL 394-403.
- 637 25. Park J-K, Han A, Czajkowski L, Reed S, Athota R, Bristol T, et al. Evaluation of  
638 Preexisting Anti-Hemagglutinin Stalk Antibody as a Correlate of Protection in a  
639 Healthy Volunteer Challenge with Influenza A/H1N1pdm Virus. *MBio*. 2018 Jan  
640 23;9(1):e02284-17.
- 641 26. Tang JW. Pre-existing immunity in human challenge studies of influenza transmission.  
642 *The Lancet Infectious Diseases*. 2012 Oct 1;12(10):744.
- 643 27. Chartered Institution of Building Services Engineers. GVA/15 CIBSE Guide A:  
644 Environmental Design 2015 [Internet]. London: CIBSE; 2015 [cited 2018 Oct 12]. 402  
645 p. Available from: [https://www.cibse.org/knowledge/knowledge-](https://www.cibse.org/knowledge/knowledge-items/detail?id=a0q20000008I79JAAS)  
646 [items/detail?id=a0q20000008I79JAAS](https://www.cibse.org/knowledge/knowledge-items/detail?id=a0q20000008I79JAAS)
- 647 28. Zaas AK, Burke T, Chen M, McClain M, Nicholson B, Veldman T, et al. A host-based  
648 RT-PCR gene expression signature to identify acute respiratory viral infection. *Sci*  
649 *Transl Med*. 2013 Sep 18;5(203):203ra126.

650 29. World Health Organization, editor. Manual for the laboratory diagnosis and virological  
651 surveillance of influenza. Geneva: World Health Organization; 2011. 139 p.

652 30. McDevitt JJ, Koutrakis P, Ferguson ST, Wolfson JM, Fabian MP, Martins M, et al.  
653 Development and Performance Evaluation of an Exhaled-Breath Bioaerosol Collector  
654 for Influenza Virus. *Aerosol Sci Technol.* 2013 Jan 1;47(4):444–51.

655

656

657 **Figure legends**

658 **Fig 1.** Schematic of study design showing timelines, environmental controls and  
659 monitoring, physical segregation arrangements, exposure intervention, and volunteer  
660 movements during quarantine study. DFA: direct fluorescence assay; RH: relative  
661 humidity; NPS: nasopharyngeal swab.

662

663 **Fig 2.** Trial profile. Intervention Recipients: wore face shields, used hand sanitizer  
664 every 15 min and only allowed to touch face with single-use wooden spatula; Control  
665 Recipients: did not use face shields or the specified hand hygiene protocol.

666

667 **Fig 3.** Viral detection in Donors by day of exposure event. A) Columns show the  
668 proportion of all infected donors (n=42) who were qRT-PCR positive for viral  
669 shedding for coarse ( $>5\mu\text{m}$ ) and fine ( $\leq 5\mu\text{m}$ ) aerosols, and nasopharyngeal swabs. B)  
670 Mean and standard deviation error bars for qRT-PCR cycle threshold values from the  
671 positive nasopharyngeal swabs (n=19 on day 1; n=34 on day 2; n=35 on day 3; n=31  
672 on day 4). C) Virus quantified from detectable exhaled coarse (n=6) and fine (n=14)  
673 breath aerosols by qRT-PCR; the boxes show the inner-quartile range (IQR) with a  
674 band to indicate the median, and whiskers extending to highest and lowest data points  
675 within 1.5 IQR.

676

677

678 **Supporting information captions**

679 **S1 Appendix. EMIT Consortium Team Members**

680 **S2 Appendix. Role of Funding Source**

681 **S3 Appendix. Efficacy of a Face Shield to Reduce Transmission of Influenza**

682 **Virus in Large Droplets.** Contains Figs. S1-S5.

683 **S4 Appendix. Full Inclusion and Exclusion Criteria, Power Calculation, and**

684 **Sample Handling**

685 **S5 Appendix. Baseline Characteristics.** Contains Table S1.


686 **S6 Appendix. Comparing the Current Study and Proof-of-Concept Study Using**

687 **Current Outcome Criteria and Applying Infection Criteria from The Proof of**

688 **Concept Study.** Contains Tables S2-S4.

689





**496 volunteers  
(HAI $\leq$ 10)**

**330 not invited or  
unavailable**

**166 entered  
quarantine**

**39 discharged before  
study start**

**127 randomised**

**52 Donors  
inoculated via  
nasal instillation  
(H3N2)**

**40  
Intervention  
Recipients**

**35  
Control  
Recipients**

**42 infected**

**0 infected**


**1 infected**

**A**

medRxiv preprint doi: <https://doi.org/10.1101/2019.12.13.19014381>; this version posted June 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Percent Positive by Sample Type

75  
50  
25  
0



Study Day

**B**

NP Swab CT Value

35  
30  
25  
20

1 2 3 4

Study Day

Log<sub>10</sub> RNA Copies

4.5  
4.0  
3.5

Coarse Fine  
Aerosol Fraction

**Sample Type**

- *Both Coarse & Fine Aerosol*
- *Coarse Aerosol*
- *Either Coarse or Fine Aerosol*
- *Fine Aerosol*
- *Nasopharyngeal (NP) Swab*

